PT3661968T - Plataforma de nanopartículas para administração de anticorpos e vacinas - Google Patents
Plataforma de nanopartículas para administração de anticorpos e vacinasInfo
- Publication number
- PT3661968T PT3661968T PT188418008T PT18841800T PT3661968T PT 3661968 T PT3661968 T PT 3661968T PT 188418008 T PT188418008 T PT 188418008T PT 18841800 T PT18841800 T PT 18841800T PT 3661968 T PT3661968 T PT 3661968T
- Authority
- PT
- Portugal
- Prior art keywords
- antibody
- vaccine delivery
- nanoparticle platform
- nanoparticle
- platform
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01078—6,7-Dimethyl-8-ribityllumazine synthase (2.5.1.78)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762541209P | 2017-08-04 | 2017-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3661968T true PT3661968T (pt) | 2022-07-04 |
Family
ID=65232668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT188418008T PT3661968T (pt) | 2017-08-04 | 2018-08-03 | Plataforma de nanopartículas para administração de anticorpos e vacinas |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200179532A1 (pt) |
EP (2) | EP4074734A1 (pt) |
JP (2) | JP7265547B6 (pt) |
CA (1) | CA3071922A1 (pt) |
DK (1) | DK3661968T3 (pt) |
ES (1) | ES2923133T3 (pt) |
PT (1) | PT3661968T (pt) |
WO (1) | WO2019023811A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210206857A1 (en) * | 2018-05-21 | 2021-07-08 | Bioprocessia Technologies Llc | Multivalent protein complexes |
BR112022001800A2 (pt) * | 2019-08-01 | 2022-04-12 | Governing Council Univ Toronto | Plataformas e métodos de nanopartículas multivalentes e multi-específicas |
EP4110384A4 (en) * | 2020-02-26 | 2024-07-31 | Wistar Inst | COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF |
CA3197642A1 (en) * | 2020-10-09 | 2022-04-14 | The Hospital For Sick Children | Polypeptides targeting sars-cov-2 and related compositions and methods |
AU2021386892A1 (en) * | 2020-11-25 | 2023-06-22 | The Hospital For Sick Children | Polypeptides targeting dr4 and/or dr5 and related compositions and methods |
MX2023008912A (es) * | 2021-01-28 | 2023-10-23 | Hospital For Sick Children | Constructos, composiciones y métodos de anticuerpos multiespecíficos multiafinidad. |
AU2022332707A1 (en) * | 2021-08-26 | 2024-03-14 | Bio Consultancy Pty Ltd | Collagen biomaterial derived from abalone |
WO2023154731A1 (en) * | 2022-02-09 | 2023-08-17 | The Regents Of The University Of California | Ligand operable protein cages |
WO2024006532A2 (en) * | 2022-06-30 | 2024-01-04 | La Jolla Institute For Immunology | Kari nanoparticle |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69434520T3 (de) | 1993-07-30 | 2009-10-15 | Affymax, Inc., Palo Alto | Biotinylierung von proteinen |
DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
EP1452601A1 (en) | 2003-02-28 | 2004-09-01 | Roche Diagnostics GmbH | Enhanced expression of fusion polypeptides with a biotinylation tag |
US20100222501A1 (en) | 2005-08-11 | 2010-09-02 | Wm. Marsh Rice University | Scalable process for synthesizing uniformly-sized composite nanoparticles |
WO2009109428A2 (en) | 2008-02-01 | 2009-09-11 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
US20100077589A1 (en) | 2008-08-29 | 2010-04-01 | Research In Motion Limited | Apparatus and method for manufacturing or repairing a circuit board |
JO3244B1 (ar) * | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
CA2921493A1 (en) * | 2012-08-21 | 2014-02-27 | Brown University | Ferritin-based tumor targeting agent, and imaging and treatment methods |
CA2925201A1 (en) | 2013-09-24 | 2015-04-02 | Massachusetts Institute Of Technology | Self-assembled nanoparticle vaccines |
TWI650607B (zh) | 2014-10-21 | 2019-02-11 | 日商Agc股份有限公司 | Euvl用附反射層之基板及其製造方法、以及euvl用反射型光罩基底及euvl用反射型光罩 |
CN107427571A (zh) | 2014-12-31 | 2017-12-01 | 美利坚合众国,由健康及人类服务部部长代表 | 基于纳米颗粒的新型多价疫苗 |
-
2018
- 2018-08-03 ES ES18841800T patent/ES2923133T3/es active Active
- 2018-08-03 CA CA3071922A patent/CA3071922A1/en active Pending
- 2018-08-03 DK DK18841800.8T patent/DK3661968T3/da active
- 2018-08-03 EP EP22158241.4A patent/EP4074734A1/en active Pending
- 2018-08-03 WO PCT/CA2018/050954 patent/WO2019023811A1/en unknown
- 2018-08-03 US US16/636,141 patent/US20200179532A1/en active Pending
- 2018-08-03 EP EP18841800.8A patent/EP3661968B1/en active Active
- 2018-08-03 PT PT188418008T patent/PT3661968T/pt unknown
- 2018-08-03 JP JP2020528499A patent/JP7265547B6/ja active Active
-
2023
- 2023-04-14 JP JP2023066391A patent/JP2023100675A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2923133T3 (es) | 2022-09-23 |
WO2019023811A1 (en) | 2019-02-07 |
JP2023100675A (ja) | 2023-07-19 |
CA3071922A1 (en) | 2019-02-07 |
EP3661968B1 (en) | 2022-03-02 |
EP3661968A1 (en) | 2020-06-10 |
EP3661968A4 (en) | 2021-05-12 |
EP4074734A1 (en) | 2022-10-19 |
DK3661968T3 (da) | 2022-06-20 |
JP7265547B6 (ja) | 2023-05-11 |
US20200179532A1 (en) | 2020-06-11 |
JP7265547B2 (ja) | 2023-04-26 |
JP2020534861A (ja) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3661968T (pt) | Plataforma de nanopartículas para administração de anticorpos e vacinas | |
IL294146A (en) | Antibody conjugates against cmet with drug and methods of using them | |
ZA201900059B (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
IL258055B (en) | Preparations and methods for administering a modified dendrimer nanoparticle vaccine | |
IL247936A0 (en) | Antibodies against egfr and drug antibody conjugates | |
ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
IL251938A0 (en) | Antibodies against CS1 and antibody-drug conjugates | |
EP3110401A4 (en) | Lipid nanoparticle vaccine adjuvants and antigen delivery systems | |
GB201615219D0 (en) | Hybrid prosthesis and delivery system | |
IL268385B (en) | Drug delivery devices and drug delivery methods | |
HUE060807T2 (hu) | Berendezés és eljárás megfelelõ záróelemek megbízható szállítására | |
GB201611639D0 (en) | Delivery device and formulation | |
GB201619561D0 (en) | Medicament delivery device and system | |
SG10201406578QA (en) | Platform for facilitating and completing transactions | |
GB201707967D0 (en) | Plasmonic nano-composites and drug delivery | |
GB201615231D0 (en) | Keeping documents secure during and after delivery | |
GB201607593D0 (en) | Peptides and nanoparticle formulations thereof | |
GB201608923D0 (en) | Drug delivery particles | |
GB201412968D0 (en) | Platinum nanoparticle conjugates for imaging and therapy |